Ovarian cancer patients during chemotherapy and nursing observation of adverse reactions.doc

 PAGE \* MERGEFORMAT 9 Ovarian cancer patients during chemotherapy and nursing observation of adverse reactions [Keywords:] ovarian cancer chemotherapy side effects nursing Chemotherapy drugs can effectively control the growth of tumor cells, ovarian cancer has become a common method of treatment. However, treatment-related adverse reactions, often makes the patient feel pain, and affecting the patients quality of life, serious treatment had to be terminated, resulting in chemotherapy can not be carried out smoothly. At present, although there are new clinical application of chemotherapy, but there is still more than half of chemotherapy patients with varying degrees of adverse reactions. Thus actively taking measures to mitigate the adverse effects caused by chemotherapy patients, to improve the quality of life of ovarian cancer, improve efficacy has a positive effect. A clinical data Right in January 2004 ~ December 2007 our hospital 49 cases of ovarian cancer observed in patients with postoperative chemotherapy, nursing care, this group of patients aged 35 to 82 years old, 37-year-old to 50 years old in 11 cases, 51-year-old to 60 years old 25 cases over 60 years old in 13 cases. Phlebitis occurred during medication in 17 cases, 42 cases of gastrointestinal adverse reactions, bone marrow suppression in 15 cases, urinary system, nervous system toxicity and injury of the three cases, liver toxicity in 1 case, patients had alopecia. Through close observation of patients, timely treatment, reducing the occurrence of adverse reactions to alleviate the symptoms of adverse reactions. 2 Nursing 2.1 The nursing method of phlebitis ① For the strong irritant drugs, the concentration should not be too high, intravenous infusion rate should not be too fast. Between the application of normal saline infusion of two drugs or 5% glucose injection to do intervals. ② should plan to start from the distal vein puncture, should be constantly changing intravenous admi